Abstract: Compounds of formula (I) as defined herein, or a pharmaceutically acceptable salt, or an in-vivo-hydrolysable ester thereof, are useful as antibacterial agents. Processes for their manufacture and pharmaceutical compositions containing them are described.

Abstract: The invention concerns a compound of formula (I), wherein, for example: R1 is of the formula —NHC(═O)(1-4C)alkyl; R2 and R3 are hydrogen or fluoro; R4 and R5 are hydrogen or methyl; >A-B- is of the formula >C═CH—, >CHCH2, or >C(OH)CH2—(> represents two single bonds); D is O, S, SO, SO2 or —NR7; wherein R7 is hydrogen, R10CO—, R10SO2—, RaOC(Rb)═CH(C═O)—, RcC(═O)C(═O)—, RdN═C(Re)C(═O)—, RfNHC(Rg)═CHC(═O)— or R14CH(R13)(CH2)m—; wherein R10 is (1-6C)alkyl [optionally substituted by, for example, hydroxy or (1-6C)alkanoyl], R11C(O)O(1-6C)alkyl or R12O—; wherein R11 is optionally substituted (1-6C)alkyl; R12 is optionally substituted (1-6C)alkyl; Ra, Rb, Rc, Rd, Re, Rf, Rg are (1-6)alkyl; m is 0 or 1; R13 is cyano; R14 is hydrogen or (1-4C)alkyl; >X—Y— is of the formula >C═CH— or >CHCH2—; and pharmaceutically acceptable salts thereof

Abstract: The invention concerns a compound of the formula (I): wherein, for example: T is of the formula (IA), (IB), or (IC); R1 is of the formula —NHC(═O)Rb wherein Rb is (1-4C)alkyl; R2 and R3 are hydrogen or fluoro; >A—B— is >C═CH— (but not when T is (IA)) or >CH—CH2—; wherein when T is of the formula (IA) or (IB); R6 is, for example, (1-4C)alkyl; R5 is hydrogen, R10CO—, R10SO2— or R10CS— wherein R10 is, for example, optionally substituted phenyl, or (1-10C)alkyl, or when T is of the formula (IA), (IB); or (IC): R5 and R6 are linked to give a 5- or 6-membered ring which is fused to the ring shown in (IA), (IB), or (IC) so as to give an optionally substituted bicyclic ring; and pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them, and their use as antibacterial agents.

Abstract: Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, 1

Abstract: The present application discloses a class of antibiotic compounds containing an oxazolidinone ring. These compounds have useful activity against Gram-positive pathogens including MRSA and MRCNS and, in particular, against various strains exhibiting resistance to vancomycin and against E. faecium strains resistant to both aminoglycosides and clinically used &bgr;-lactams. The compounds also possess a favourable toxicological profile. This invention further relates to processes for their preparation, to intermediates useful in their preparation, to their use as therapeutic agents and to pharmaceutical compositions containing them.

Abstract: The invention concerns a compound of the formula (I): wherein, for example: R1 is of the formula —NHC(═O)Rb wherein Rb is, for example, (1-4C)alkyl; R2 and R3 are hydrogen or fluoro; R2 and R3 are hydrogen or fluoro; D is O; R4 and R5 are hydrogen, (1-4C)alkyl or AR-oxymethyl; AR is phenyl or phenyl(1-4C)alkyl; R6 is hydrogen; >A—B— is of the formula >C═C(Ra)—, >CHCHRa—, or >C(OH)CHRa— (> represents two single bonds) wherein Ra is hydrogen or (1-4C)alkyl; and pharmaceutically-acceptable salts thereof; processes for their preparation; pharmaceutical compositions containing them and their use as antibacterial agents.

Abstract: A compound of formula (I): wherein R1 is hydroxy or of the formula —NHC(═O)(1-4C)alkyl or —NHS(O)n(1-4C)alkyl wherein n is 0, 1 or 2; R2 and R3 are independently hydrogen or fluoro; R4 and R5 are independently hydrogen or methyl; >A—B— is of the formula >C═CH—, or >C(OH)CH2—; >X—Y— is of the formula >C=CH—, or >CHCH2—; and D is S, SO, or SO2; or a pharmaceutically-acceptable salt thereof.

Abstract: The present invention relates to antibiotic compounds and in particular to antibiotic compounds containing an oxazolidinone ring. This invention further relates to processes for their preparation, to intermediates useful in their preparation, to their use as therapeutic agents and to pharmaceutical compositions containing them.

Abstract: The invention concerns a compound of formula (I), ##STR1## wherein, for example: R.sup.1 is of the formula --NHC(.dbd.O) (1-4C) alkyl; R.sup.2 and R.sup.3 are hydrogen or fluoro; R.sup.4 and R.sup.5 are hydrogen or methyl; >A--B-- is of the formula >C.dbd.CH--, >CHCH.sub.2, or >C(OH)CH.sub.2 -- (> represents two single bonds); D is O, S, SO, SO.sub.2 or --NR.sup.7 ; wherein R.sup.7 is hydrogen, R.sup.10 CO--, R.sup.10 SO.sub.2 --, R.sup.a OC(R.sup.b).dbd.CH(C.dbd.O)--, R.sup.c C(.dbd.O)C(.dbd.O)--, R.sup.d N.dbd.C(R.sup.e)C(.dbd.O)--, R.sup.f NHC(R.sup.g).dbd.CHC(.dbd.O)-- or R.sup.14 CH(R.sup.13)(CH.sub.2).sub.m --; wherein R.sup.10 is (1-6 C)alkyl [optionally substituted by, for example, hydroxy or (1-6 C)alkanoyl], R.sup.11 C(O)O(1-6 C)alkyl or R.sup.12 O--; wherein R.sup.11 is optionally substituted (1-6 C)alkyl; R.sup.12 is optionally substituted (1-6 C)alkyl; R.sup.a, R.sup.b, R.sup.c, R.sup.d, R.sup.e, R.sup.f, R.sup.g are (1-6 C)alkyl; m is 0 or 1; R.sup.13 is cyano; R.sup.

Abstract: The invention concerns a compound of formula (I): ##STR1## wherein R.sup.1 -R.sup.6, A, B, and D have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising such a compound or salt, and methods of treating a bacterial infection by administering such a compound or salt.